RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Chinese PLA General Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorChinese PLA General Hospital中国人民解放军总医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05948033, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with histologically confirmed lymphoma including the following types defined by the World Health Organization(WHO) 2016:HL,Aggressive B-cell non-Hodgkin's lymphoma(Diffuse large B-cell lymphoma,High grade B-cell lymphoma,burkitt's lymphoma,Mantle cell lymph,Anaplastic large cell lymphoma, etc.) and Indolent lymphoma(Including but not limited to follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, etc.)

    Inclusion criterion 3

    PR as best response after at least 6 cycles and biopsy-proven residual disease or disease progression ≤ 6 months of therapy, or

    Inclusion criterion 7

    Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or relapsed less than or equal to 12 months of ASCT (must have biopsy prove recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy.

    Inclusion criterion 8

  3. Relapse after treatment with ≥2 lines systemic therapy for all the above disease types. Relapse disease is defined as disease progression after last regimen. Refractory disease is defined as no CR tofirst-line therapy:

    Inclusion criterion 4

    SD as best response after at least 4 cycles of first-line therapy (eg, 4 cycles of R- CHOP), or

    Inclusion criterion 6

    Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment;

    Exclusion criterion 2

    Previous or concurrent cancer within 5 years prior to treatment start except for curatively treated cervical cancer in situ, non-melanoma skin cancer, local prostate cancer after radical surgery ;

    Exclusion criterion 10

    Previously received targeting CD70 therapy;

    Exclusion criterion 13

  4. ECOG performance status ≤2 and Estimated life expectancy of more than 3 months;

    Inclusion criterion 2

  5. Functions of important organs meet the following requirements:ANC≥≥1×10\^9/L; Platelet count ≥50×10\^9/L; Hemoglobin ≥80 g/L;Serum AST and serum ALT, ≤3.0 x ULN (≤5 x ULN for patients with liver metastases); Total serum bilirubin ≤3.0 x ULN); Serum creatinine ≤1.5xULN ; Echocardiography showed left ventricular ejection fraction ≥50%.Pulmonary function: oxygen saturation of blood (SaO2) ≥92% in indoor air environment.

    Inclusion criterion 13

  6. According to Lugano response criteria 2014, there should be at least one evaluable tumor focus. Evaluable tumor focus was defined as that with the longest diameter of intranodal focus > 1.5cm, the longest diameter of extranodal focus > 1.0cm assessed by computed tomography (CT) ormagnetic resonance imaging (MRI).

    Inclusion criterion 12

  7. Known positive test result for human immunodeficiency virus (HIV) oracquired immune deficiency syndrome (AIDS);Active infection of hepatitis B virus (HBV), or hepatitis C virus (HCV);

    Exclusion criterion 5

  8. Pregnancy tests for women of childbearing age shall be negative;Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year.

    Inclusion criterion 15

    Pregnant, lactating, or breastfeeding females;

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05948033, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Patients eligible for inclusion in this study had to meet all of the following criteria:

  • Age 18-75 (inclusive);
  • ECOG performance status ≤2 and Estimated life expectancy of more than 3 months;
  • Patients with histologically confirmed lymphoma including the following types defined by the World Health Organization(WHO) 2016:HL,Aggressive B-cell non-Hodgkin's lymphoma(Diffuse large B-cell lymphoma,High grade B-cell lymphoma,burkitt's lymphoma,Mantle cell lymph,Anaplastic large cell lymphoma, etc.) and Indolent lymphoma(Including but not limited to follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, etc.)
  • Relapse after treatment with ≥2 lines systemic therapy for all the above disease types. Relapse disease is defined as disease progression after last regimen. Refractory disease is defined as no CR tofirst-line therapy:
  • PD as best response to first-line therapy, or
  • SD as best response after at least 4 cycles of first-line therapy (eg, 4 cycles of R- CHOP), or
  • PR as best response after at least 6 cycles and biopsy-proven residual disease or disease progression ≤ 6 months of therapy, or
  • Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or relapsed less than or equal to 12 months of ASCT (must have biopsy prove recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy.
  • Individuals must have received adequate prior therapy.
  • CD70 antigen expression percentage ≥ 10%.
  • Successful leukapheresis assessment and preculture of T cells;
  • According to Lugano response criteria 2014, there should be at least one evaluable tumor focus. Evaluable tumor focus was defined as that with the longest diameter of intranodal focus > 1.5cm, the longest diameter of extranodal focus > 1.0cm assessed by computed tomography (CT) ormagnetic resonance imaging (MRI).
  • Functions of important organs meet the following requirements:ANC≥≥1×10\^9/L; Platelet count ≥50×10\^9/L; Hemoglobin ≥80 g/L;Serum AST and serum ALT, ≤3.0 x ULN (≤5 x ULN for patients with liver metastases); Total serum bilirubin ≤3.0 x ULN); Serum creatinine ≤1.5xULN ; Echocardiography showed left ventricular ejection fraction ≥50%.Pulmonary function: oxygen saturation of blood (SaO2) ≥92% in indoor air environment.
  • Toxicity from previous antitumor therapy ≤ grade 1 (according to CTCAE version 5.0) or to an acceptable level of inclusion/exclusion criteria (other toxicities such as alopecia and vitiligo considered by the investigator to pose no safety risk to the subject).
  • Pregnancy tests for women of childbearing age shall be negative;Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year.
  • Ability to understand and sign a written informed consent documen.

Exclusion Criteria:

  • Subjects are being treated with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.
  • Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment;
  • Pregnant, lactating, or breastfeeding females;
  • Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
  • Known positive test result for human immunodeficiency virus (HIV) oracquired immune deficiency syndrome (AIDS);Active infection of hepatitis B virus (HBV), or hepatitis C virus (HCV);
  • History of allergy or intolerance to study drug components;
  • Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation;
  • Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered.
  • Known brain metastases or active central nervous system(CNS) has been involved
  • Previous or concurrent cancer within 5 years prior to treatment start except for curatively treated cervical cancer in situ, non-melanoma skin cancer, local prostate cancer after radical surgery ;
  • Any serious underlying medical (eg, pulmonary, renal,hepatic,gastrointestinal, or neurological) or psychiatric condition or any issue that would limit compliance with study requirements;
  • Vaccination within 30 days of study enrollment;
  • Previously received targeting CD70 therapy;
  • Being participating any other trials or withdraw within 4 weeks;
  • Researchers believe that other reasons are not suitable for clinicaltrials.

Quoted from ClinicalTrials.gov, NCT05948033, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05948033, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05948033